Stockscreener 앱 받기
13.68
3.73%
-0.53
시장 영업 전:
13.95
0.27
+1.97%
Assembly Biosciences Inc 주식(ASMB)의 최신 뉴스
JPMorgan Chase & Co. Boosts Holdings in Assembly Biosciences, Inc. (NASDAQ:ASMB) - Defense World
Reviewing Assembly Biosciences (NASDAQ:ASMB) and CytoDyn (OTCMKTS:CYDY) - Defense World
When the Price of (ASMB) Talks, People Listen - Stock Traders Daily
AC Immune (NASDAQ:ACIU) & Assembly Biosciences (NASDAQ:ASMB) Head-To-Head Review - Defense World
(ASMB) Technical Pivots with Risk Controls - Stock Traders Daily
Geode Capital Management LLC Has $712,000 Stock Position in Assembly Biosciences, Inc. (NASDAQ:ASMB) - Defense World
Gilead raises Assembly Bio stake to ~30% - MSN
ABI-4334 shows promise in hepatitis B Phase 1b trial: Data - Liver Disease News
Trend Tracker for (ASMB) - Stock Traders Daily
Assembly Biosciences (NASDAQ:ASMB) Share Price Passes Above 200 Day Moving AverageHere's What Happened - MarketBeat
Assembly Biosciences extends lease through 2029 By Investing.com - Investing.com Nigeria
Assembly Biosciences extends lease through 2029 - Investing.com India
Brokerages Set TKO Group Holdings, Inc. (NYSE:TKO) PT at $136.79 - Defense World
Financial Analysis: Assembly Biosciences (NASDAQ:ASMB) vs. LifeVantage (NASDAQ:LFVN) - Defense World
Assembly Biosciences director Houghton buys $49,997 in stock By Investing.com - Investing.com Australia
Assembly Biosciences director Houghton buys $49,997 in stock - Investing.com India
Assembly Biosciences, Inc. (NASDAQ:ASMB) Director Acquires $49,983.22 in Stock - MarketBeat
Gilead Buys $20.1 Million of Assembly Biosciences Stock - MSN
Assembly Biosciences, Inc. (NASDAQ:ASMB) Sees Large Drop in Short Interest - MarketBeat
(ASMB) Long Term Investment Analysis - Stock Traders Daily
Assembly Biosciences’ (ASMB) “Neutral” Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright maintains Neutral on Assembly Biosciences stock By Investing.com - Investing.com Canada
Assembly Biosciences' (ASMB) Neutral Rating Reiterated at HC Wainwright - MarketBeat
Assembly Biosciences Shares Rise on Results from Hepatitis B Drug Trial - MarketWatch
Assembly Bio stock spikes on Gilead-partnered drug (ASMB:NASDAQ) - Seeking Alpha
Assembly Biosciences reports positive phase 1b HBV drug results - Investing.com
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B - The Manila Times
Assembly Bio's ABI-4334 Shows Strong HBV Antiviral Activity in Phase 1b Trial2.9 Log DNA Reduction - StockTitan
Gilead Sciences invests $20.1 million in Assembly Biosciences By Investing.com - Investing.com India
Fmr LLC Purchases 3,635 Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) - Defense World
Assembly Biosciences (NASDAQ:ASMB) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Assembly Biosciences (NASDAQ:ASMB) Shares Pass Above 200 Day Moving AverageHere's Why - MarketBeat
Gilead invests in Assembly Bio to advance clinical programs - The Pharma Letter
Gilead boosts stake in Assembly Bio with $30.1 million investment By Investing.com - Investing.com Canada
Assembly Biosciences strikes amended deal with Gilead - Investing.com
Assembly Biosciences strikes amended deal with Gilead By Investing.com - Investing.com UK
Assembly Bio stock rises as Gilead ups stake (ASMB:NASDAQ) - Seeking Alpha
Assembly Biosciences Shares Rise 19% After Gilead Investment, Funding - MarketWatch
Assembly Biosciences Gets $30.1M Equity Investment, Funding From Gilead - MarketWatch
Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs - The Manila Times
Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from - The Bakersfield Californian
Assembly Bio Secures $30.1M Gilead Investment, Advancing Ambitious Antiviral Pipeline - StockTitan
0.82%
0.53%
자본화:
|
볼륨(24시간):